Product image of Lafactin (Venlafaxine) supplied by GNH India

Lafactin

Active Ingredient:
Venlafaxine
Origin:
EU

Lafactin (Venlafaxine)

Venlafaxine, the active ingredient in Lafactin, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder and several anxiety disorders in adult patients.

GNH India supplies Lafactin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Manufacturer / TM Owner

Aurovitas Pharma Polska Sp. Z O.O

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Venlafaxine acts on the serotonin and norepinephrine pathways and is indicated for several mood and anxiety disorders.
  • Major depressive disorder: alleviates depressive symptoms and improves functional outcomes.
  • Generalized anxiety disorder: reduces excessive worry and associated physical tension.
  • Social anxiety disorder: diminishes fear of social situations and improves interpersonal functioning.
  • Panic disorder: lowers the frequency and severity of panic attacks.

How It Works

  • Venlafaxine inhibits the reuptake of serotonin and norepinephrine at therapeutic doses, increasing their concentrations in the synaptic cleft. At higher doses it also modestly blocks dopamine reuptake. This combined neurotransmitter enhancement restores mood balance and reduces anxiety by modulating central nervous system signaling pathways.

Side Effects

Venlafaxine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea
  • Headache
  • Dry mouth
  • Insomnia
  • Dizziness
  • Sweating

Serious or Rare Side Effects

  • Elevated blood pressure or hypertension
  • Serotonin syndrome (confusion, hyperthermia, muscle rigidity)
  • Severe hyponatremia (low sodium levels)
  • Suicidal thoughts or behavior, especially early in treatment
  • Severe skin reactions (e.g., Stevens‑Johnson syndrome)
  • Cardiac arrhythmias or QT prolongation

Precautions & Warnings

  • When prescribing venlafaxine, clinicians should consider several safety precautions.
  • Blood pressure monitoring: check regularly as the drug can raise systolic and diastolic pressure.
  • Suicidality risk: monitor for worsening depression or emergence of suicidal thoughts, especially early in treatment.
  • Serotonin syndrome: avoid concomitant serotonergic agents and watch for symptoms such as agitation, hyperreflexia, and fever.
  • Hyponatremia: assess serum sodium in at‑risk patients, particularly the elderly.
  • Pregnancy category: use only if the potential benefit justifies the potential risk to the fetus.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Venlafaxine interacts with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome.
  • Other serotonergic agents (e.g., SSRIs, tramadol): heightened serotonin syndrome risk.
  • St. John’s wort: may increase serotonergic activity.
  • Thioridazine: can cause QT prolongation.
  • Linezolid: potent serotonergic effect.

Moderate Interactions (Monitor Closely)

  • NSAIDs and anticoagulants: increased bleeding risk.
  • Antihypertensives: venlafaxine may attenuate blood‑pressure‑lowering effect.
  • CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise venlafaxine plasma levels.
  • Alcohol: may enhance central nervous system depression.
  • Lithium: monitor for additive serotonergic effects.

Frequently Asked Questions

Lafactin, containing venlafaxine, is indicated for major depressive disorder and several anxiety‑related conditions, including generalized anxiety disorder, social anxiety disorder, and panic disorder. It helps alleviate mood symptoms and reduce excessive worry in adult patients.

Venlafaxine blocks the reuptake of serotonin and norepinephrine, increasing their levels in the brain’s synaptic cleft. This dual neurotransmitter enhancement restores mood balance and diminishes anxiety by modulating central nervous system pathways.

The appropriate dose of Lafactin is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Lafactin is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as venlafaxine is excreted in breast milk.

To order Lafactin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lafactin (venlafaxine) is an SNRI, offering dual inhibition of serotonin and norepinephrine, whereas SSRIs primarily affect serotonin alone. This broader mechanism can be advantageous for patients who do not respond adequately to SSRIs, but it may also carry a higher risk of blood‑pressure elevation and certain side effects.

Lafactin should be stored at temperatures below 25 °C in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use it after the expiration date.

Lafactin is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious risks include elevated blood pressure, serotonin syndrome, severe hyponatremia, and the emergence of suicidal thoughts, particularly during the early phases of treatment. Patients should be monitored closely for these events and seek immediate medical attention if they occur.

Lafactin should be avoided in patients currently taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to venlafaxine. Caution is also advised for individuals with uncontrolled hypertension, severe liver impairment, or a history of serotonin syndrome.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.